Concepts (80)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2021 | 3 | 0.720 |
Why?
|
| Infarction, Posterior Cerebral Artery | 1 | 2021 | 7 | 0.720 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 125 | 0.630 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 246 | 0.430 |
Why?
|
| Multiple Sclerosis | 1 | 2016 | 218 | 0.420 |
Why?
|
| Quality of Life | 1 | 2016 | 1228 | 0.310 |
Why?
|
| Leukoaraiosis | 2 | 2019 | 45 | 0.280 |
Why?
|
| Stroke | 5 | 2024 | 1196 | 0.270 |
Why?
|
| White Matter | 2 | 2019 | 123 | 0.260 |
Why?
|
| Patient Admission | 1 | 2024 | 198 | 0.190 |
Why?
|
| Basal Ganglia Hemorrhage | 1 | 2020 | 3 | 0.170 |
Why?
|
| Bed Rest | 1 | 2019 | 11 | 0.160 |
Why?
|
| Vitamin K | 1 | 2019 | 16 | 0.160 |
Why?
|
| Middle Aged | 7 | 2024 | 17612 | 0.150 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 67 | 0.150 |
Why?
|
| Mechanical Thrombolysis | 1 | 2019 | 37 | 0.150 |
Why?
|
| Hematoma | 1 | 2019 | 81 | 0.150 |
Why?
|
| Leukoencephalopathies | 1 | 2019 | 25 | 0.150 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 190 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Male | 10 | 2024 | 29897 | 0.140 |
Why?
|
| Echocardiography | 1 | 2021 | 501 | 0.140 |
Why?
|
| Ischemic Attack, Transient | 1 | 2019 | 96 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2024 | 3294 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 209 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Interview, Psychological | 1 | 2016 | 78 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 107 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1101 | 0.120 |
Why?
|
| Trochlear Nerve Diseases | 1 | 2015 | 1 | 0.120 |
Why?
|
| Abducens Nerve Diseases | 1 | 2015 | 2 | 0.120 |
Why?
|
| Cranial Nerves | 1 | 2015 | 7 | 0.120 |
Why?
|
| Polycythemia Vera | 1 | 2015 | 7 | 0.120 |
Why?
|
| Arthritis, Juvenile | 1 | 2015 | 8 | 0.120 |
Why?
|
| Etanercept | 1 | 2015 | 32 | 0.120 |
Why?
|
| Brain Ischemia | 1 | 2019 | 419 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 2172 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2019 | 495 | 0.120 |
Why?
|
| Sarcoidosis | 1 | 2015 | 34 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 2015 | 57 | 0.110 |
Why?
|
| Uveitis | 1 | 2015 | 34 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2019 | 2570 | 0.110 |
Why?
|
| Self Report | 1 | 2016 | 375 | 0.110 |
Why?
|
| Cognition Disorders | 1 | 2015 | 217 | 0.100 |
Why?
|
| Female | 10 | 2024 | 32882 | 0.100 |
Why?
|
| Humans | 12 | 2024 | 63459 | 0.100 |
Why?
|
| Aged | 8 | 2024 | 14448 | 0.100 |
Why?
|
| Comorbidity | 1 | 2016 | 1122 | 0.100 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 221 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 615 | 0.100 |
Why?
|
| Retrospective Studies | 6 | 2019 | 6659 | 0.090 |
Why?
|
| Prevalence | 1 | 2016 | 1380 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2575 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1553 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2017 | 834 | 0.070 |
Why?
|
| Adult | 3 | 2019 | 16824 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 5461 | 0.060 |
Why?
|
| Time Factors | 2 | 2024 | 3771 | 0.060 |
Why?
|
| Hospital Costs | 1 | 2024 | 126 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2019 | 5684 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2024 | 407 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 68 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2019 | 53 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 369 | 0.040 |
Why?
|
| Brain | 2 | 2017 | 1552 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 5356 | 0.030 |
Why?
|
| Radiography | 1 | 2019 | 550 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2019 | 288 | 0.030 |
Why?
|
| Triage | 1 | 2017 | 126 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 978 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1094 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 671 | 0.030 |
Why?
|
| Infliximab | 1 | 2015 | 50 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 80 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1148 | 0.030 |
Why?
|
| Aspirin | 1 | 2015 | 171 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1654 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 378 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1644 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2081 | 0.020 |
Why?
|